%D9%85%D9%88%D9%83%D8%B3%D9%8A%D9%81%D9%84%D9%88%D9%83%D8%B3%D8%A7%D8%B3%D9%8A%D9%86%D9%85%D9%88%DA%A9%D8%B3%DB%8C_%D9%81%D9%84%D9%88%DA%A9%D8%B3%D8%A7%D8%B3%DB%8C%D9%86MocsifflocsacinMoxifloxacinMoxifloxacinMoxifloxacino%D9%85%D9%88%DA%A9%D8%B3%DB%8C_%D9%81%D9%84%D9%88%DA%A9%D8%B3%D8%A7%D8%B3%DB%8C%D9%86MoksifloksasiiniMoxifloxacine%D5%84%D5%B8%D6%84%D5%BD%D5%AB%D6%86%D5%AC%D6%85%D6%84%D5%BD%D5%A1%D6%81%D5%AB%D5%B6Moxifloxacina%E3%83%A2%E3%82%AD%E3%82%B7%E3%83%95%E3%83%AD%E3%82%AD%E3%82%B5%E3%82%B7%E3%83%B3%EB%AA%A9%EC%8B%9C%ED%94%8C%EB%A1%9D%EC%82%AC%EC%8B%A0%E0%AC%AE%E0%AD%8B%E0%AC%95%E0%AD%8D%E0%AC%B8%E0%AC%BF%E0%AC%AB%E0%AD%8D%E0%AC%B2%E0%AD%8B%E0%AC%95%E0%AD%8D%E0%AC%B8%E0%AC%BE%E0%AC%B8%E0%AC%BF%E0%AC%A8MoksyfloksacynaMoxifloxacinaMoxifloxacin%C4%83%D0%9C%D0%BE%D0%BA%D1%81%D0%B8%D1%84%D0%BB%D0%BE%D0%BA%D1%81%D0%B0%D1%86%D0%B8%D0%BDMoksifloksacinMoksifloksacin%E0%B8%A1%E0%B8%AD%E0%B8%81%E0%B8%8B%E0%B8%B4%E0%B8%9F%E0%B8%A5%E0%B8%AD%E0%B8%81%E0%B8%8B%E0%B8%B2%E0%B8%8B%E0%B8%B4%E0%B8%99%D0%9C%D0%BE%D0%BA%D1%81%D0%B8%D1%84%D0%BB%D0%BE%D0%BA%D1%81%D0%B0%D1%86%D0%B8%D0%BDMoxifloxacinQ424940%E8%8E%AB%E8%A5%BF%E6%B2%99%E6%98%9F
about
gonorrheaBruschtfiewerconjunctivitissinusitisEscherichia coli infectious diseasebacteroides infectious diseaseacute bronchitisgram-negative bacterial infectionurinary tract infectioncystitisupper respiratory tract infectionstaphylococcal infectionbacterial pneumoniapyelonephritisurinary tract infectionPseudomonas infection
P2176
Clinical Study to Evaluate Effect on QT/QTc Interval After Multiple Dose of CelecoxibNexGen EBA Radiologic and Immunologic Biomarkers of Sterilizing Drug Activity in TuberculosisMeasurement of Anti-TB Drugs in Lung Tissue From Patients Having Surgery to Treat TuberculosisClinical Trial to Investigate the Pharmacokinetics of Second-Line Anti-Tuberculosis AgentsA Bioequivalence Study of Norgestimate /Ethinyl Estradiol (NGM/EE) Tablets Manufactured at 2 Different FacilitiesPopulation Pharmacokinetics of Anti-tuberculosis Drugs in Children With TuberculosisThorough QT/QTC (TQT) Clinical Trial to Evaluate the Effect of Zoliflodacin on Cardiac Repolarization in Healthy Male and Female SubjectsAdequate Duration of Antibiotic Treatment in Community-acquired Pneumonia With High Risk Class and Adequate Initial Clinical ResponseNGS-Guided(G) Regimens(R) of Anti-tuberculosis(A) Drugs for the Control(C) and Eradication(E) of MDR-TBA Phase 1, Randomized, Placebo-and Positive-Controlled Crossover Study to Determine the Effect of Single-Dose GC4419 on QTc Interval in Healthy VolunteersA Phase 1 Study To Evaluate The Effect Of Glasdegib On The Cardiac Repolarization In Healthy SubjectsA Study to Evaluate the Cardiac Safety of a Single Dose of AL-335 Administered on a Background of Simeprevir and Odalasvir and of Repeated Doses of Odalasvir Administered Alone in Healthy ParticipantsAcceptability of the NuvaRing Among StudentsStudy to Evaluate the Efficacy and Safety of Moxifloxacin Versus Amoxicillin/Clavulanate in the Treatment of Acute Bacterial RhinosinusitisTherapy of Complicated Intra-Abdominal Infections With Moxifloxacin or ErtapenemBAY12-8039: 5 Days for Sinusitis vs PlaceboPhase 1 Thorough QT Study in Young Healthy VolunteersEsomeprazole, Moxifloxacin and Amoxicilin for Rescue Therapy of Helicobacter Pylori InfectionA Trial Comparing Moxifloxacin Versus Levofloxacin Plus Metronidazole In Uncomplicated Pelvic Inflammatory DiseaseA Randomized, Multiple Dose, Double Blind, 5-way Crossover Study of the Electrocardiographic (ECG) Effects of BilastineAcute Cholecystitis - Early Laparoscopic Surgery Versus Antibiotic Therapy and Delayed Elective CholecystectomySafety Study on the Effect of Eurartesim™ on QT/QTc Interval Compared to Riamet in Healthy VolunteersMoxifloxacin i.v. in the Treatment of Complicated Intra-Abdominal Infection (cIAI)Antibiotic or Not in Non-purulent Exacerbations of COPD: a Trial of Security and EfficacyBioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy AdultsSafety and Efficacy of Moxidex OticMoxifloxacin in Pediatric Subjects With Complicated Intra-abdominal InfectionStudy to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)An Efficacy and Safety Study Comparing Oral Contraceptive Containing Norgestimate or Desogestrel for Acne TreatmentA Thorough QT Study of TR-701free Acid (FA) in Healthy SubjectsA Study on the Effects of LY2409021 on the Electrical Impulses of the HeartA Study of the Effect of Dulaglutide on How the Body Handles Oral Contraceptive in Healthy Female Participants2-Site Safety Study of Besivance Versus Vigamox Prophylactically in Routine Cataract SurgeryTo Investigate the Effect of Intravenous Ondansetron on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult SubjectsThe Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy VolunteersEfficacy and Safety Study of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial PneumoniaThorough QT Study to Evaluate the Effects of BI 207127 (Deleobuvir) Combined With Faldaprevir on Cardiac Safety Parameters in Healthy Subjects.Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract SurgeryControlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary TuberculosisVEG111485: A QTc Study of Pazopanib
P4844
probucolclarithromycinpimozideazithromycindroperidol(RS)-methadoneerythromycinhaloperidoldofetilideibutilidechlorpromazineanagrelidedronedarone(RS)-citalopramondansetronamiodaronequinidinesotalolcocainepentamidineprocainamideterfenadinesevofluraneflecainidesulpiridechloroquineastemizoleescitalopramdomperidonedisopyramidecisapridebepridilthioridazinemesoridazinearsenic trioxideHalofantrinesparfloxacin
P769
Q101896-28D706A4-7853-45DF-B51A-11E5B8977EC7Q12192-141D4FE3-E511-44DA-B95D-3D559A1101D3Q167844-066ADFBC-5659-4ABE-AC76-D9A683C0E848Q183344-A7B8ECE1-39E2-4BEE-B26A-C58E74131D42Q18975220-4F07E897-1570-4A7B-8F9A-29A12B191557Q18975970-1FCF135D-ED46-4742-8218-6648472BFF4BQ1900400-A8FC7968-070D-428E-881D-460BC6D1D267Q19597369-97CE261E-F21D-4BC3-B5ED-778A9FEBC0C1Q221668-C1B2366F-6049-499D-BA3D-E79AA46A637DQ246084-08A98D91-C8CA-474E-87DD-DA8C2BA94B54Q2622199-0DD0E5BC-8D3C-460B-A89D-4D5DC1421D08Q34879-EB1FD3E2-0E2F-4421-8C98-31B63DE3EB23Q3776920-F664A3A5-E753-406D-97F1-2D3A2909174AQ506652-FF12D66A-D486-45E2-ADC5-4528BD558F62Q55779861-48F7DF83-F374-43EC-B86F-04E134E5077FQ7255052-3C4C0D24-D661-42AD-849D-E311D527F8E8
P2176
Q61728008-041E2A06-AE55-45A0-88E3-D4D6C0355E43Q61864695-717B5327-51ED-4DB9-8EE4-5F9F5BC421F8Q61865065-1CE755C9-D0B2-4B4B-B71A-A620D6CA5FCDQ61894565-E114E387-CD86-40F1-8C39-39E17EEA7B52Q61894623-B7FF1287-5E1A-4144-8DE4-4B84BCD6DB0FQ61904384-29C200AC-2075-4A0E-8A9E-B2531E806E55Q61905056-776C4649-5835-4773-886D-83C5F14F67C9Q61906988-AD7C9A3A-C64A-4137-8F71-7E7E5A1C777DQ61907366-0DD4F951-FB0E-4A0D-845D-26AE1F6324F5Q61908940-6FFAB96B-892C-48E1-BC53-2740ABD7E146Q61909059-F8EF2075-73FB-424A-9A0F-FEDFC7C959ADQ61909627-9DCE2F3D-EDAC-4E9F-9244-CA2D1DF52F86Q61915399-B0BA252A-3753-49FC-8BD6-9D19151759F7Q61917838-C1648EAE-3D6A-45C8-82E2-1DEDDF7ECD15Q61917865-29FF5B40-FEFA-404E-9673-E75F42293C0CQ61917918-5809CFF4-05B0-4398-8BD2-1635A0539A68Q61918491-DA4B156C-AD2F-4484-BB0D-D5DED9D7A553Q61920602-5292F6CB-A0D4-471E-A054-1911D020F462Q61920805-9F53AA1C-4E36-45E3-83B3-F3712171804BQ61922038-8876452C-81CE-4F02-B309-862A9B8C43CAQ61924325-E6FDC7D2-A5C1-46E3-B928-63C5E351D062Q61935753-C3AB365B-4357-4D98-8160-417A081F469DQ61936550-C650A9C0-3947-42C6-B76B-2E1E8B78589CQ61937077-9C78ECD7-67BC-43EB-92AB-B83FBEBBD8BCQ61938409-7D48F27E-602D-4BA2-80C3-6322BF1D13E8Q61938633-CFB6C9A2-8F37-45EE-B1A6-A79B3DAEAE8CQ61938872-7DFC63A3-9E24-468F-9A9B-A23241ABACE7Q61956096-CDF3F8D8-833D-46D1-BDCE-F742310EB145Q61956290-3349AB47-963A-49CF-B3CD-ADD9BE024FF1Q61957247-1D3465EB-8469-4BF7-BA01-8779E51051F5Q61965708-63FCFDBF-468D-4294-8468-CB1A752C7035Q61965898-EB80A209-3827-4B3F-B46A-00B0CA6F0306Q61966165-7CDF64E3-0B89-46E8-A89F-BB5205025717Q61967636-A457D569-32AB-4B80-A41A-D385DC037BDCQ61969394-5F9908C0-E56B-429C-982B-E3519EE9D891Q61975491-A441BE9A-87F6-4B57-ABEC-F880F071F138Q61975763-BCC730DA-8E8E-4FF9-B8BA-3E8421C6A413Q61980671-38D286EA-D9D3-4B1F-89A4-674DF09984A3Q61981168-16AA2114-C085-41B5-9909-D51C92ACBD4AQ61981444-7437314C-0641-46CB-9FB0-AC2FC03F6D35
P4844
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Moksifloksacin
@sh
Moksifloksasiini
@fi
Moxifloxacin
@de
Moxifloxacin
@nl
Moxifloxacin
@vi
Moxifloxacino
@es
Moxifloxacină
@ro
mocsifflocsacin
@cy
moksifloksacin
@nn
moksyfloksacyna
@pl
type
label
Moksifloksacin
@sh
Moksifloksasiini
@fi
Moxifloxacin
@de
Moxifloxacin
@nl
Moxifloxacin
@vi
Moxifloxacino
@es
Moxifloxacină
@ro
mocsifflocsacin
@cy
moksifloksacin
@nn
moksyfloksacyna
@pl
altLabel
1-Cyclopropyl-6-fluoro-1,4-dih ...... oxo-3-quinolinecarboxylic acid
@cy
1-Cyclopropyl-6-fluoro-1,4-dih ...... oxo-3-quinolinecarboxylic acid
@en
151096-09-2
@fr
Avelox
@ar
C21H24F1N3O4
@it
C21H24FN3O4
@fr
Moxifloxacin
@ar
Moxifloxacin
@en
Moxifloxacinhydrochlorid
@de
Vigamox
@ar
prefLabel
Moksifloksacin
@sh
Moksifloksasiini
@fi
Moxifloxacin
@de
Moxifloxacin
@nl
Moxifloxacin
@vi
Moxifloxacino
@es
Moxifloxacină
@ro
mocsifflocsacin
@cy
moksifloksacin
@nn
moksyfloksacyna
@pl